Vestal Point Capital LP Purchases 410,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Vestal Point Capital LP increased its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 31.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,725,000 shares of the company’s stock after purchasing an additional 410,000 shares during the period. Vestal Point Capital LP owned 2.44% of Ventyx Biosciences worth $3,760,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in shares of Ventyx Biosciences in the second quarter valued at about $32,000. Bank of New York Mellon Corp raised its stake in Ventyx Biosciences by 58.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 230,593 shares of the company’s stock valued at $533,000 after purchasing an additional 84,984 shares during the period. Rhumbline Advisers lifted its holdings in Ventyx Biosciences by 38.0% in the 2nd quarter. Rhumbline Advisers now owns 90,331 shares of the company’s stock worth $209,000 after purchasing an additional 24,885 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Ventyx Biosciences during the 2nd quarter valued at approximately $608,000. Finally, American Century Companies Inc. bought a new stake in shares of Ventyx Biosciences during the second quarter valued at approximately $60,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Insider Activity

In other news, CEO Raju Mohan bought 261,752 shares of the stock in a transaction dated Monday, November 25th. The stock was purchased at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the acquisition, the chief executive officer now owns 2,175,028 shares of the company’s stock, valued at $4,371,806.28. The trade was a 13.68 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 18.18% of the company’s stock.

Ventyx Biosciences Trading Up 4.3 %

Shares of NASDAQ:VTYX opened at $2.65 on Friday. The company has a 50-day moving average price of $2.20 and a 200 day moving average price of $2.62. Ventyx Biosciences, Inc. has a 12 month low of $1.67 and a 12 month high of $11.48. The company has a market cap of $187.38 million, a price-to-earnings ratio of -1.12 and a beta of 0.37.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group cut their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 target price (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Wells Fargo & Company dropped their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, HC Wainwright restated a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Ventyx Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.